U.S. Markets closed

Repros Therapeutics Inc. (RPRX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.39-0.02 (-4.13%)
At close: 4:00PM EDT
People also watch
SNSSTHLDCYCCOPXAOGXI

Repros Therapeutics Inc.

2408 Timberloch Place
Suite B-7
The Woodlands, TX 77380
United States
281-719-3400
http://www.reprosrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedAge
Ms. Katherine A. Anderson CPACFO, Chief Accounting Officer & Sec.344.87kN/A59
Dr. Larry M. Dillaha M.D.Chief Exec. Officer, Pres and DirectorN/AN/A53
Dr. Joachim F. Wernicke M.D., Ph.D.Chief Medical OfficerN/AN/A69
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio include Proellex that is in Phase III clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis; and enclomiphene, a single isomer of clomiphene citrate, which is in Phase III clinical trials for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The company was founded in 1987 and is based in The Woodlands, Texas.

Corporate Governance

Repros Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.